In PathwayPrism s Latest Iteration, BioAnalytics Group Takes Over Development from BioSoftware | GenomeWeb

PathwayPrism, one of the first pathway-analysis software products to hit the market, has had a tangled history over the last few years, but now it's back in the hands of one of its original developers, who believes that there is still plenty of opportunity for the technology.

Scott Lett, CEO of the BioAnalytics Group, told BioInform this week that his firm is now developing a new version of PathwayPrism, which he helped develop at Physiome Sciences before the company was acquired by Predix Pharmaceuticals in 2003 [BioInform 09-01-03].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.